Mustang Bio (NASDAQ:MBIO) Rating Increased to Hold at Wall Street Zen

Mustang Bio (NASDAQ:MBIO) was upgraded by stock analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a note issued to investors on Saturday.

Mustang Bio Price Performance

Shares of Mustang Bio stock opened at $1.25 on Friday. The business’s fifty day moving average price is $1.27 and its two-hundred day moving average price is $4.96. The company has a market capitalization of $4.13 million, a P/E ratio of -0.02 and a beta of 2.27. Mustang Bio has a 1-year low of $1.01 and a 1-year high of $65.00.

Mustang Bio (NASDAQ:MBIO) last posted its quarterly earnings data on Wednesday, May 14th. The company reported ($0.05) EPS for the quarter. On average, research analysts expect that Mustang Bio will post -35 earnings per share for the current fiscal year.

Institutional Trading of Mustang Bio

A hedge fund recently raised its stake in Mustang Bio stock. Geode Capital Management LLC lifted its position in Mustang Bio, Inc. (NASDAQ:MBIO) by 15.9% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 284,437 shares of the company’s stock after buying an additional 38,951 shares during the period. Geode Capital Management LLC owned approximately 29.63% of Mustang Bio worth $50,000 at the end of the most recent reporting period. 9.95% of the stock is currently owned by institutional investors.

About Mustang Bio

Mustang Bio, Inc, a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.